[go: up one dir, main page]

UY33472A - ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?. - Google Patents

?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.

Info

Publication number
UY33472A
UY33472A UY0001033472A UY33472A UY33472A UY 33472 A UY33472 A UY 33472A UY 0001033472 A UY0001033472 A UY 0001033472A UY 33472 A UY33472 A UY 33472A UY 33472 A UY33472 A UY 33472A
Authority
UY
Uruguay
Prior art keywords
quinolin
piperazin
fluoro
amino
methyl
Prior art date
Application number
UY0001033472A
Other languages
English (en)
Inventor
Thakur Jeewan
Qiu Zhihui
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY33472A publication Critical patent/UY33472A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición farmacéutica para su administración oral, la cual comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1H-bencimidazol-2-il]-1H-quinolin-2-ona, un relleno en una cantidad del 15 al 70 por ciento en peso, un desintegrante en una cantidad de menos del 15 por ciento en peso, un derrapante y/o un lubricante en una cantidad del 0.1 al 10 por ciento en peso, en donde las cantidades en peso se basan en el peso total de la composición.
UY0001033472A 2010-06-30 2011-06-28 ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?. UY33472A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10168028 2010-06-30

Publications (1)

Publication Number Publication Date
UY33472A true UY33472A (es) 2012-01-31

Family

ID=42751565

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033472A UY33472A (es) 2010-06-30 2011-06-28 ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.

Country Status (38)

Country Link
US (1) US9545402B2 (es)
EP (2) EP3446686A1 (es)
JP (1) JP6043281B2 (es)
KR (2) KR101840182B1 (es)
CN (2) CN103068373A (es)
AR (1) AR081776A1 (es)
AU (1) AU2011273519B2 (es)
BR (1) BR112012033479A8 (es)
CA (1) CA2801826C (es)
CL (1) CL2012003729A1 (es)
CO (1) CO6650354A2 (es)
CR (1) CR20120623A (es)
CU (1) CU20120177A7 (es)
DK (1) DK2588086T3 (es)
DO (1) DOP2012000324A (es)
EA (1) EA026244B1 (es)
EC (1) ECSP13012411A (es)
ES (1) ES2701161T3 (es)
GE (1) GEP20146049B (es)
GT (1) GT201200348A (es)
HU (1) HUE042355T2 (es)
IL (1) IL223799A (es)
MA (1) MA34387B1 (es)
MX (1) MX345404B (es)
MY (2) MY163369A (es)
NI (1) NI201200189A (es)
NZ (1) NZ604055A (es)
PE (1) PE20130481A1 (es)
PH (1) PH12012502519A1 (es)
PL (1) PL2588086T3 (es)
PT (1) PT2588086T (es)
SG (1) SG186182A1 (es)
TN (1) TN2012000574A1 (es)
TR (1) TR201818761T4 (es)
TW (1) TWI583384B (es)
UA (1) UA109659C2 (es)
UY (1) UY33472A (es)
WO (1) WO2012001074A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013116293A1 (en) 2012-01-31 2013-08-08 Novartis Ag Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer
BR112015000349A2 (pt) 2012-07-11 2017-06-27 Novartis Ag método de tratamento de tumores estromais gastrointestinais
US9395468B2 (en) 2012-08-27 2016-07-19 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
JP6752140B2 (ja) * 2013-03-14 2020-09-09 アイミューン セラピューティクス，インコーポレイテッド 経口脱感作のための落花生処方物の製造
WO2015073758A1 (en) 2013-11-15 2015-05-21 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
US20150343075A1 (en) * 2014-06-02 2015-12-03 Aimmune Therapeutics Placebo formulations and uses thereof
WO2016094533A1 (en) 2014-12-09 2016-06-16 Ocular Dynamics, Llc Medical device coating with a biocompatible layer
TWI790189B (zh) 2015-01-02 2023-01-21 美商梅拉洛伊卡公司 細菌組成物
EP3297609A1 (en) * 2015-05-22 2018-03-28 Novartis AG Pharmaceutical compositions
MX2020004683A (es) 2017-11-02 2020-08-13 Aimmune Therapeutics Inc Metodos de inmunoterapia oral.
WO2020037151A1 (en) 2018-08-16 2020-02-20 Aimmune Therapeutics, Inc. Peanut oral immunotherapy with maintenance dose
JP2022514645A (ja) 2018-12-20 2022-02-14 アイミューン セラピューティクス，インコーポレイテッド ピーナツ経口免疫療法において投与が欠落した場合の投与スケジュール
CN113966229A (zh) 2019-05-10 2022-01-21 爱沐疗法公司 用于改善花生过敏患者的生活质量的方法
US10835531B1 (en) 2019-06-18 2020-11-17 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
WO2022026851A1 (en) * 2020-07-31 2022-02-03 The Scripps Research Institute Targeted rna degradation allows precision repurposing of protein-targeted small molecule medicines to rna
WO2025067365A1 (zh) * 2023-09-27 2025-04-03 南京迈诺威医药科技有限公司 含有别孕烷醇酮衍生物的药物组合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009897A (en) * 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
PL211125B1 (pl) 2000-09-11 2012-04-30 Novartis Vaccines & Diagnostic Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie
KR20050037585A (ko) 2002-08-23 2005-04-22 카이론 코포레이션 벤지미다졸 퀴놀리논 및 그들의 사용
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
GB0504203D0 (en) * 2005-03-01 2005-04-06 Novartis Ag Organic compounds
EP1904480A2 (en) * 2005-05-23 2008-04-02 Novartis Pharma AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
US20070042034A1 (en) * 2005-07-22 2007-02-22 Myriad Genetics, Incorporated High drug load formulations and dosage forms
RU2433826C2 (ru) 2005-11-29 2011-11-20 Новартис Аг Композиции хинолинонов
CN101316593B (zh) * 2005-11-29 2012-05-02 诺瓦提斯公司 喹啉酮类的制剂
AU2008226582B2 (en) 2007-03-09 2011-07-21 Novartis Ag Treatment of melanoma
CN101835472A (zh) 2007-11-08 2010-09-15 埃姆比特生物科学公司 N-(5-叔丁基-异噁唑-3-基)-N′-{4-[7-(2-吗啉-4-基-乙氧基)咪唑并[2,1-b][1,3]苯并噻唑-2-基]苯基}脲治疗增殖性疾病的给药方法
PE20091628A1 (es) 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
EP2108365A1 (en) * 2008-04-09 2009-10-14 LEK Pharmaceuticals d.d. Single dosage pharmaceutical formulation comprising eprosartan mesylate
MX2012012058A (es) 2010-04-16 2012-11-22 Novartis Ag Combinacion de compuestos organicos.

Also Published As

Publication number Publication date
MX2012015091A (es) 2013-02-12
NI201200189A (es) 2013-12-17
GEP20146049B (en) 2014-02-25
WO2012001074A3 (en) 2012-03-22
DK2588086T3 (en) 2019-01-07
AR081776A1 (es) 2012-10-17
TWI583384B (zh) 2017-05-21
MY163369A (en) 2017-09-15
SG186182A1 (en) 2013-01-30
EP2588086B1 (en) 2018-09-12
CA2801826A1 (en) 2012-01-05
ES2701161T3 (es) 2019-02-21
CR20120623A (es) 2013-02-11
GT201200348A (es) 2014-03-14
DOP2012000324A (es) 2013-02-28
KR20170139170A (ko) 2017-12-18
CL2012003729A1 (es) 2013-04-12
CA2801826C (en) 2018-04-10
BR112012033479A2 (pt) 2016-11-29
IL223799A (en) 2017-04-30
HUE042355T2 (hu) 2019-06-28
EP2588086A2 (en) 2013-05-08
CN106943355A (zh) 2017-07-14
BR112012033479A8 (pt) 2017-10-31
KR20130091319A (ko) 2013-08-16
TW201206903A (en) 2012-02-16
PT2588086T (pt) 2018-12-18
CO6650354A2 (es) 2013-04-15
CU20120177A7 (es) 2013-04-19
MX345404B (es) 2017-01-30
MA34387B1 (fr) 2013-07-03
AU2011273519A1 (en) 2013-01-31
KR101840182B1 (ko) 2018-03-19
MY177741A (en) 2020-09-23
TN2012000574A1 (en) 2014-04-01
EA201291410A1 (ru) 2013-05-30
TR201818761T4 (tr) 2019-01-21
WO2012001074A2 (en) 2012-01-05
EA026244B1 (ru) 2017-03-31
CN106943355B (zh) 2020-09-01
UA109659C2 (xx) 2015-09-25
CN103068373A (zh) 2013-04-24
EP3446686A1 (en) 2019-02-27
JP6043281B2 (ja) 2016-12-14
US20130090344A1 (en) 2013-04-11
PL2588086T3 (pl) 2019-04-30
JP2013530196A (ja) 2013-07-25
US9545402B2 (en) 2017-01-17
PE20130481A1 (es) 2013-05-01
AU2011273519B2 (en) 2014-05-15
ECSP13012411A (es) 2013-03-28
NZ604055A (en) 2015-02-27
PH12012502519A1 (en) 2021-06-23

Similar Documents

Publication Publication Date Title
UY33472A (es) ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
GT201000182A (es) Regimen de dosificacion asociado con ésteres de paliperidona inyectables de acción prolongada
CY1122786T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
UY32923A (es) Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico
GT201400111A (es) Triazolopiridinas sustituidas
AR078159A1 (es) Composicion que contiene palmitoil-etanolamida ultra-micronizada .metodo. compuesto.forma polimorfica.
HN2011003011A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
MX2013003365A (es) Composicion farmaceutica.
BR112015011430A2 (pt) composição para liberação imediata e prolongada
BR112012024673A2 (pt) composição anestésica termogelificante
CR20130239A (es) Compuestos de triazolopiridina
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
CU20120171A7 (es) Triazolopiridinas sustituidas
CO6741223A2 (es) Derivados de azetidina útiles para el tratamiento de enfermedades metabólicas e inflamatorias
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
BR112014032759A2 (pt) composições lipídicas de racecadotril
EA201991287A1 (ru) Твердые фармацевтические композиции на основе тикагрелора для перорального применения
CO6450623A2 (es) Parasiticidas sanguineos
MX2017007856A (es) Composicion para el cuidado bucal.
PE20170305A1 (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida
BR112015012220A2 (pt) composição simbiótica e uso da mesma
BR112014015193A8 (pt) composição enriquecida com glicoproteína como um aditivo para alimento e/ou ração e/ou como um agente terapêutico
ECSP088897A (es) 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzotiazepinas, su preparación, composiciones que las contienen y utilización

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200615